ArticlePloS one2019
Lubiprostone as a potential therapeutic agent to improve intestinal permeability and prevent the development of atherosclerosis in apolipoprotein E-deficient mice.
Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- Gut-derived bacterial extracellular vesicles: the microbial dark matter contributing to host inflammation and cardiometabolic disease.Gut microbes · 2026Review
- Comparative Effectiveness of Lubiprostone and Stool Softeners on Risk of Kidney Outcomes in Patients with CKD.Clinical journal of the American Society of Nephrology : CJASN · 2025Article
- Intestinal CD4Nature communications · 2025Article
- Circulating bacterial DNA in cardiovascular disease.Frontiers in cardiovascular medicine · 2025Review
- Intestinal mucosal barrier: a potential target for traditional Chinese medicine in the treatment of cardiovascular diseases.Frontiers in pharmacology · 2024Review
- Alleviation of cholestatic liver injury and intestinal permeability by lubiprostone treatment in bile duct ligated rats: role of intestinal FXR and tight junction proteins claudin-1, claudin-2, and occludin.Naunyn-Schmiedeberg's archives of pharmacology · 2023Article
- The ClC-2 Chloride Channel Activator, Lubiprostone, Improves Intestinal Barrier Function in Biopsies from Crohn's Disease but Not Ulcerative Colitis Patients.Pharmaceutics · 2023Article
- Enhancing intestinal barrier efficiency: A novel metabolic diseases therapy.Frontiers in nutrition · 2023Review
- Sivelestat Alleviates Atherosclerosis by Improving Intestinal Barrier Function and Reducing Endotoxemia.Frontiers in pharmacology · 2022Article
- Metabolic drivers of non-alcoholic fatty liver disease.Molecular metabolism · 2021Review
- The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target.International journal of molecular sciences · 2021Review
- The Types and Proportions of Commensal Microbiota Have a Predictive Value in Coronary Heart Disease.Journal of clinical medicine · 2021Review
- Endotoxins and Non-Alcoholic Fatty Liver Disease.Frontiers in endocrinology · 2021Review
- Intestinal barrier dysfunction as a therapeutic target for cardiovascular disease.American journal of physiology. Heart and circulatory physiology · 2020Review
- Gut microbiota and atherosclerosis: role of B cell for atherosclerosis focusing on the gut-immune-B2 cell axis.Journal of molecular medicine (Berlin, Germany) · 2020Review
- Intestinal fatty acid-binding protein mediates atherosclerotic progress through increasing intestinal inflammation and permeability.Journal of cellular and molecular medicine · 2020Article
- Intestinal Barrier Dysfunction, LPS Translocation, and Disease Development.Journal of the Endocrine Society · 2020Article
- Lactulose for prevention of cardiovascular events after myocardial infarction: A retrospective cohort study.JRSM cardiovascular diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The interaction between atherosclerosis and commensal microbes through leaky gut syndrome (LGS), which is characterized by impaired intestinal permeability and the introduction of undesired pathogens into the body, has not been fully elucidated. Our aim was to investigate the potential role of a ClC-2 chloride channel activator, lubiprostone, which is reported to have beneficial effects on LGS, in the development of atherosclerosis in apolipoprotein E-deficient (ApoE-/-) mice. After a 15-week feeding period of a Western diet (WD), ApoE-/- mice were treated with a Western-type diet (WD) alone or WD with oral supplementation of lubiprostone for 10 weeks. This feeding protocol was followed by experimental evaluation of LGS and atherosclerotic lesions in the aorta. In mice with lubiprostone, in vivo translocation of orally administered 4-kDa FITC-dextran was significantly improved, and RNA expression of the epithelial tight junction proteins, Zo-1 and occludin, was significantly up-regulated in the ileum, compared to the WD alone group, suggesting a possible reversal of WD-induced intestinal barrier dysfunction. As a result, WD-induced exacerbation of atherosclerotic lesion formation was reduced by 69% in longitudinally opened aortas and 26% in aortic root regions. In addition, there was a significant decrease in circulating immunoglobulin level, followed by an attenuation of inflammatory responses in the perivascular adipose tissue, as evidenced by reduced expression of pro-inflammatory cytokines and chemokines. Lubiprostone attenuates atherosclerosis by ameliorating LGS-induced inflammation through the restoration of the intestinal barrier. These findings raise the possibility of targeting LGS for the treatment of atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.